<unk>  is almost exclusively metabolized by CYP3A4. As such, its levels in the body may be altered by inhibitors and inducers of CYP3A4. (For a list of CYP3A4 inhibitors and inducers, see here.) However, in spite of the fact<unk>  is metabolized by CYP3A4, there is no evidence of clinically significant drug interactions when<unk>  at a dosage of 150 mg/day or less is co-administered with drugs that inhibit or induce cytochrome P450 enzyme activity. Because<unk>  circulates at relatively high concentrations and is highly protein-bound, it has the potential to displace other highly protein-bound drugs like warfarin, phenytoin, theophylline, and aspirin from plasma binding proteins. This could, in turn, result in increased free concentrations of such drugs and increased effects and/or side effects, potentially necessitating dosage adjustments.<unk>  has specifically been found to displace coumarin anticoagulants like warfarin from their plasma binding proteins (namely albumin) in vitro, potentially resulting in an increased anticoagulant effect, and for this reason, close monitoring of prothrombin time and dosage adjustment as necessary is recommended when<unk>  is used in combination with these drugs. However, in spite of this, no conclusive evidence of an interaction between<unk>  and other drugs was found in clinical trials of nearly 3,000 patients.
Bicalutamide
Darolutamide
Topilutamide
Apalutamide
Nilutamide
Acetothiolutamide
Flutamide
Enzalutamide